Specific Changes: On page BINV-J:

Add footnote: The 12-gene recurrence test (EndoPredict from Myriad Genetics) can be used to identify women with a low risk of recurrence in the 5-10 year range that may be spared endocrine therapy beyond 5 years.

Rationale: Clinical uncertainty still exists around the benefit of extended endocrine therapy among women with early stage, ER+, HER- breast cancer. In two studies, EndoPredict has been shown identify patients with a very low risk of recurrence (1.8-4.3%) in the 5-10 year time frame\textsuperscript{1,2} who are therefore unlikely to benefit in a clinically meaningful way from extended endocrine therapy.
References


Sincerely,

Johnathan Lancaster, MD, PhD
Chief Medical Officer
Myriad Genetic Laboratories Inc.